Hormone-Refractory Oncology Drug Global Market Report 2026

Description

Hormone-refractory oncology drugs are therapeutic agents used for the treatment of cancers that no longer respond to hormone-based therapies. These drugs act by targeting alternative biological pathways when hormonal control becomes ineffective. They are commonly used in advanced or treatment-resistant cancer cases to slow disease progression and enhance patient outcomes.

The primary drug types of hormone-refractory oncology drug include anti-androgens, aromatase inhibitors, estrogen receptor modulators, gonadotropin releasing hormone agonists/antagonists, and other drug types. Anti-androgens refer to therapeutic agents that block the action of androgens at receptor sites, helping to slow or inhibit the growth of hormone-sensitive cancer cells in refractory conditions. These solutions are based on therapy approaches such as monotherapy and combination therapy and they are administered through oral and injectable routes. They are various distributions such as hospital pharmacies, retail pharmacies, and online pharmacies and the various applications involved are prostate cancer, breast cancer, and other cancers.

Tariffs are influencing the hormone-refractory oncology drugs market by increasing the cost of imported active pharmaceutical ingredients, biologics, and advanced oncology drug formulations utilized in resistant cancer treatment. This is affecting supply chains for targeted therapies, immunotherapy agents, and specialized injectable formulations, especially in import-dependent regions such as Asia Pacific and parts of Latin America. Drug manufacturers operating through hospital and retail pharmacy channels are experiencing pricing pressure and delayed procurement cycles due to rising landed costs. However, tariffs are also encouraging local pharmaceutical manufacturing, strengthening regional biotech production capabilities, and accelerating investments in domestic oncology drug development ecosystems, thereby improving long-term supply resilience.

The hormone-refractory oncology drug market research report is one of a series of new reports from The Business Research Company that provides hormone-refractory oncology drug market statistics, including hormone-refractory oncology drug industry global market size, regional shares, competitors with a hormone-refractory oncology drug market share, detailed hormone-refractory oncology drug market segments, market trends and opportunities, and any further data you may need to thrive in the hormone-refractory oncology drug industry. This hormone-refractory oncology drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hormone-refractory oncology drug market size has grown rapidly in recent years. It will grow from $3.93 billion in 2025 to $4.4 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to increasing prevalence of prostate and breast cancer cases globally, growing reliance on hormone therapy in early stage cancer treatment, expansion of oncology drug research and clinical trials, rising adoption of chemotherapy and endocrine therapy combinations, increasing healthcare expenditure on cancer treatment and hospital oncology infrastructure.

The hormone-refractory oncology drug market size is expected to see rapid growth in the next few years. It will grow to $6.95 billion by 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to growth in precision medicine and biomarker based oncology treatments, increasing development of next generation targeted cancer therapies, rising adoption of combination immunotherapy and small molecule drugs, expansion of personalized oncology treatment pathways in hospitals, increasing regulatory approvals for advanced refractory cancer drugs. Major trends in the forecast period include increasing adoption of targeted kinase inhibitors and next generation biologics for resistant cancer types, rising use of combination therapy approaches to overcome hormone resistance in oncology treatment, expansion of precision oncology enabling biomarker driven treatment selection for advanced cancers, growing development of immunotherapy based alternatives for hormone refractory cancer management, increasing shift toward oral oncology drugs for improved patient compliance in long term treatment.

The increasing prevalence of hormone-resistant cancers is expected to propel the growth of the hormone-refractory oncology drug market going forward. Hormone-Resistant Cancers are cancers that continue to grow or spread despite treatment with hormone-blocking therapies, such as castration-resistant prostate cancer (CRPC) or endocrine-resistant breast cancer. The rising prevalence of hormone-resistant cancers is driven by prolonged exposure to endocrine (hormone) therapies, which is contributing to tumor cells adapting and developing resistance mechanisms over time. Hormone-refractory oncology drug development supports and propels the management of these resistant disease states by providing targeted therapeutic options when conventional hormone therapies fail, thereby strengthening treatment outcomes. For instance, in October 2025, according to NHS England, a UK-based publicly funded healthcare system, there were 354,820 new cancer diagnoses in 2023, which is 8,605 more than in 2022. Therefore, the increasing prevalence of hormone-resistant cancers is driving the growth of the hormone-refractory oncology drug market.

Leading companies operating in the hormone-refractory oncology drug market are focusing on biomarker-driven targeted therapies that inhibit specific molecular pathways responsible for resistance to hormone therapy. Biomarker-driven targeted therapies refer to treatments designed to identify genetic alterations and selectively block signaling pathways that enable tumor growth after endocrine therapy failure. For example, in November 2023, AstraZeneca, a UK-based pharmaceutical company, received U. S. Food and Drug Administration (FDA) approval for Truqap (capivasertib) for use in combination with fulvestrant for the treatment of hormone receptor-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations following disease progression. This therapy selectively inhibits the AKT signaling pathway and incorporates biomarker-based patient selection to improve treatment outcomes. The approval was supported by positive Phase III CAPItello-291 trial results demonstrating improved progression-free survival in patients with these genetic alterations, strengthening AstraZeneca's oncology portfolio and expanding treatment options for patients with hormone-resistant breast cancer.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer strengthened its oncology portfolio by integrating advanced antibody-drug conjugate (ADC) technologies, expanded its precision oncology capabilities to address treatment-resistant cancers, and enhanced its global market reach through a broader and more differentiated pipeline. Seagen Inc. is a US-based biotechnology company developing targeted cancer therapies, with a core focus on antibody-drug conjugates designed to selectively deliver cytotoxic agents to tumor cells.

Major companies operating in the hormone-refractory oncology drug market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S. A., Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Incyte Corporation, Ipsen S. A., Exelixis Inc., Arvinas Inc., Nuvation Bio Inc., Immunic Inc., Noxopharm Limited, Accutar Biotechnology Inc.

North America was the largest region in the hormone-refractory oncology drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormone-refractory oncology drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the hormone-refractory oncology drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hormone-refractory oncology drugs market consists of sales of abiraterone acetate tablets, enzalutamide capsules, docetaxel injection, cabazitaxel injection, mitoxantrone injection, prednisone tablets, hydrocortisone tablets, and zoledronic acid injection. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hormone-Refractory Oncology Drug Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses hormone-refractory oncology drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hormone-refractory oncology drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hormone-refractory oncology drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

Markets Covered:1) By Drug Type: Anti-Androgens; Aromatase Inhibitors; Estrogen Receptor Modulators; Gonadotropin Releasing Hormone Agonists/Antagonists; Other Drug Types
2) By Therapy Approach: Monotherapy; Combination Therapy
3) By Route Of Administration: Oral; Injectable
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By Application: Prostate Cancer; Breast Cancer; Other Cancers
Subsegments:
1) By Anti-Androgens: Non Steroidal Anti Androgens; Steroidal Anti Androgens; Second Generation Anti Androgens
2) By Aromatase Inhibitors: Non Steroidal Aromatase Inhibitors; Steroidal Aromatase Inhibitors
3) By Estrogen Receptor Modulators: Selective Estrogen Receptor Modulators; Selective Estrogen Receptor Degraders
4) By Gonadotropin Releasing Hormone Agonists / Antagonists: Gonadotropin Releasing Hormone Agonists; Gonadotropin Releasing Hormone Antagonists
5) By Other Drug Types: Androgen Biosynthesis Inhibitors; Targeted Kinase Inhibitors; Immunotherapy Agents
Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Pfizer Inc.; AbbVie Inc.; Bayer AG; Sanofi S.A.; Novartis AG; AstraZeneca plc; Bristol-Myers Squibb Company; GlaxoSmithKline plc; Eli Lilly and Company; Takeda Pharmaceutical Company Limited; Amgen Inc.; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Incyte Corporation; Ipsen S.A.; Exelixis Inc.; Arvinas Inc.; Nuvation Bio Inc.; Immunic Inc.; Noxopharm Limited; Accutar Biotechnology Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Product Code: PP5MHLFT02_G26Q2

1. Executive Summary

1.1. Key Market Insights (2020-2035)
1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
1.3. Major Factors Driving the Market
1.4. Top Three Trends Shaping the Market

2. Hormone-Refractory Oncology Drug Market Characteristics

2.1. Market Definition & Scope
2.2. Market Segmentations
2.3. Overview of Key Products and Services
2.4. Global Hormone-Refractory Oncology Drug Market Attractiveness Scoring And Analysis
- 2.4.1. Overview of Market Attractiveness Framework
- 2.4.2. Quantitative Scoring Methodology
- 2.4.3. Factor-Wise Evaluation
Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation
2.4.5. Strategic Implications and Recommendations

3. Hormone-Refractory Oncology Drug Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem
3.2. List Of Key Raw Materials, Resources & Suppliers
3.3. List Of Major Distributors and Channel Partners
3.4. List Of Major End Users

4. Global Hormone-Refractory Oncology Drug Market Trends And Strategies

4.1. Key Technologies & Future Trends
- 4.1.1 Biotechnology, Genomics & Precision Medicine
- 4.1.2 Artificial Intelligence & Autonomous Intelligence
- 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
- 4.1.4 Industry 4.0 & Intelligent Manufacturing
- 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
4.2. Major Trends
- 4.2.1 Increasing Adoption Of Targeted Kinase Inhibitors And Next Generation Biologics For Resistant Cancer Types
- 4.2.2 Rising Use Of Combination Therapy Approaches To Overcome Hormone Resistance In Oncology Treatment
- 4.2.3 Expansion Of Precision Oncology Enabling Biomarker Driven Treatment Selection For Advanced Cancers
- 4.2.4 Growing Development Of Immunotherapy Based Alternatives For Hormone Refractory Cancer Management
- 4.2.5 Increasing Shift Toward Oral Oncology Drugs For Improved Patient Compliance In Long Term Treatment

5. Hormone-Refractory Oncology Drug Market Analysis Of End Use Industries

5.1 Hospitals And Oncology Clinics
5.2 Cancer Research Institutes
5.3 Specialty Oncology Centers
5.4 Retail And Hospital Pharmacies
5.5 Other End Users

6. Hormone-Refractory Oncology Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Hormone-Refractory Oncology Drug Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Hormone-Refractory Oncology Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Hormone-Refractory Oncology Drug Market Size, Comparisons And Growth Rate Analysis
7.3. Global Hormone-Refractory Oncology Drug Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Hormone-Refractory Oncology Drug Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Hormone-Refractory Oncology Drug Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Hormone-Refractory Oncology Drug Market Segmentation

9.1. Global Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Anti-Androgens, Aromatase Inhibitors, Estrogen Receptor Modulators, Gonadotropin Releasing Hormone Agonists/Antagonists, Other Drug Types
9.2. Global Hormone-Refractory Oncology Drug Market, Segmentation By Therapy Approach, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Monotherapy, Combination Therapy
9.3. Global Hormone-Refractory Oncology Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Oral, Injectable
9.4. Global Hormone-Refractory Oncology Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
9.5. Global Hormone-Refractory Oncology Drug Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Prostate Cancer, Breast Cancer, Other Cancers
9.6. Global Hormone-Refractory Oncology Drug Market, Sub-Segmentation Of Anti-Androgens, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Non Steroidal Anti Androgens, Steroidal Anti Androgens, Second Generation Anti Androgens
9.7. Global Hormone-Refractory Oncology Drug Market, Sub-Segmentation Of Aromatase Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Non Steroidal Aromatase Inhibitors, Steroidal Aromatase Inhibitors
9.8. Global Hormone-Refractory Oncology Drug Market, Sub-Segmentation Of Estrogen Receptor Modulators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Selective Estrogen Receptor Modulators, Selective Estrogen Receptor Degraders
9.9. Global Hormone-Refractory Oncology Drug Market, Sub-Segmentation Of Gonadotropin Releasing Hormone Agonists / Antagonists, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Gonadotropin Releasing Hormone Agonists, Gonadotropin Releasing Hormone Antagonists
9.10. Global Hormone-Refractory Oncology Drug Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Androgen Biosynthesis Inhibitors, Targeted Kinase Inhibitors, Immunotherapy Agents

10. Hormone-Refractory Oncology Drug Market Regional And Country Analysis

10.1. Global Hormone-Refractory Oncology Drug Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Hormone-Refractory Oncology Drug Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Hormone-Refractory Oncology Drug Market

11.1. Asia-Pacific Hormone-Refractory Oncology Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Hormone-Refractory Oncology Drug Market

12.1. China Hormone-Refractory Oncology Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Hormone-Refractory Oncology Drug Market

13.1. India Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Hormone-Refractory Oncology Drug Market

14.1. Japan Hormone-Refractory Oncology Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Hormone-Refractory Oncology Drug Market

15.1. Australia Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Hormone-Refractory Oncology Drug Market

16.1. Indonesia Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Hormone-Refractory Oncology Drug Market

17.1. South Korea Hormone-Refractory Oncology Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Hormone-Refractory Oncology Drug Market

18.1. Taiwan Hormone-Refractory Oncology Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Hormone-Refractory Oncology Drug Market

19.1. South East Asia Hormone-Refractory Oncology Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Hormone-Refractory Oncology Drug Market

20.1. Western Europe Hormone-Refractory Oncology Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Hormone-Refractory Oncology Drug Market

21.1. UK Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Hormone-Refractory Oncology Drug Market

22.1. Germany Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Hormone-Refractory Oncology Drug Market

23.1. France Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Hormone-Refractory Oncology Drug Market

24.1. Italy Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Hormone-Refractory Oncology Drug Market

25.1. Spain Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Hormone-Refractory Oncology Drug Market

26.1. Eastern Europe Hormone-Refractory Oncology Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Hormone-Refractory Oncology Drug Market

27.1. Russia Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Hormone-Refractory Oncology Drug Market

28.1. North America Hormone-Refractory Oncology Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Hormone-Refractory Oncology Drug Market

29.1. USA Hormone-Refractory Oncology Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Hormone-Refractory Oncology Drug Market

30.1. Canada Hormone-Refractory Oncology Drug Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Hormone-Refractory Oncology Drug Market

31.1. South America Hormone-Refractory Oncology Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Hormone-Refractory Oncology Drug Market

32.1. Brazil Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Hormone-Refractory Oncology Drug Market

33.1. Middle East Hormone-Refractory Oncology Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Hormone-Refractory Oncology Drug Market

34.1. Africa Hormone-Refractory Oncology Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Hormone-Refractory Oncology Drug Market, Segmentation By Drug Type, Segmentation By Therapy Approach, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Hormone-Refractory Oncology Drug Market Regulatory and Investment Landscape

36. Hormone-Refractory Oncology Drug Market Competitive Landscape And Company Profiles

36.1. Hormone-Refractory Oncology Drug Market Competitive Landscape And Market Share 2024
- 36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Hormone-Refractory Oncology Drug Market - Company Scoring Matrix
- 36.2.1. Market Revenues
- 36.2.2. Product Innovation Score
- 36.2.3. Brand Recognition
36.3. Hormone-Refractory Oncology Drug Market Company Profiles
- 36.3.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 36.3.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 36.3.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Hormone-Refractory Oncology Drug Market Other Major And Innovative Companies

Bayer AG, Sanofi S.A., Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Incyte Corporation, Ipsen S.A., Exelixis Inc., Arvinas Inc.

38. Global Hormone-Refractory Oncology Drug Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Hormone-Refractory Oncology Drug Market

41. Hormone-Refractory Oncology Drug Market High Potential Countries, Segments and Strategies

41.1 Hormone-Refractory Oncology Drug Market In 2030 - Countries Offering Most New Opportunities
41.2 Hormone-Refractory Oncology Drug Market In 2030 - Segments Offering Most New Opportunities
41.3 Hormone-Refractory Oncology Drug Market In 2030 - Growth Strategies
- 41.3.1 Market Trend Based Strategies
- 41.3.2 Competitor Strategies

42. Appendix

42.1. Abbreviations
42.2. Currencies
42.3. Historic And Forecast Inflation Rates
42.4. Research Inquiries
42.5. The Business Research Company
42.6. Copyright And Disclaimer